Latest News

(UroToday.com)  There have been transformational changes in first-line therapy for patients with advanced renal cell carcinoma (RCC) in the past three years. Foremost among these is the move from monotherapy to combination approaches. While CheckMate 214 first brought combination therapy with dual checkpoint inhibition (nivolumab and ipilimumab) to the forefront, subsequent studies have examined combinations […]

(UroToday.com) During bipolar androgen therapy (BAT), intramuscular testosterone is administered, which results in rapid cycling of serum T levels from supraphysiologic to near-castrate in men with metastatic castration resistant prostate cancer (mCRPC).1 It has previously been observed that anecdotal clinical responses to immune checkpoint blockade in mCRPC patients previously treated with BAT occur and it has […]

(UroToday.com) The Plenary agenda of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting included a session, entitled “So Your Patient with Kidney or Bladder Cancer Responded to Immunotherapy: What’s Next?”. In this context, Dr. Tom Powles from Barts Cancer Institute discussed whether we can consider immunotherapy a truly curative approach for patients with advanced […]

(UroToday.com)  The Plenary agenda of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting included a session, entitled “So Your Patient with Kidney or Bladder Cancer Responded to Immunotherapy: What’s Next?”. In this context, Dr. Mamta Parikh from UC Davis Comprehensive Cancer Center discussed considerations for the treatment of patients who respond well to […]

(UroToday.com) Survival rates are low for patients with metastatic urothelial carcinoma after disease progression with platinum-based chemotherapy, but the use of immune checkpoint inhibitors as second-line therapy has shown improved outcomes. The PD-1 inhibitor pembrolizumab is the only second-line therapy recommended for use after platinum-based chemotherapy, based on the phase 3 KEYNOTE-045 trial that showed significantly […]

(UroToday.com) Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy and pelvic lymph node dissection improves survival compared to radical cystectomy and pelvic lymph node dissection alone for patients with muscle-invasive bladder cancer.1 Neoadjuvant gemcitabine-cisplatin is standard for patients with muscle-invasive bladder cancer and can result in pathologic downstaging to non-muscle-invasive bladder cancer (< pT2N0) at radical cystectomy, […]

(UroToday.com) The standard of care for patients with muscle-invasive bladder cancer consists of neoadjuvant chemotherapy and radical cystectomy or chemoradiotherapy. However, radical cystectomy is associated with potential morbidity or mortality from the procedure. TAR-200 is an intravesical drug-delivery system designed for the local continuous release of gemcitabine within the bladder:

(UroToday.com) Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy improves overall survival (OS) in muscle-invasive bladder cancer, but about half of patients are cisplatin-unfit or refuse it. Neoadjuvant immune checkpoint inhibitors can induce a high pathologic complete response rate (ypT0N0). The combination of anti-PD-1 (nivolumab) and anti-KIR (lirilumab) is hypothesized to be safe and has significant activity […]

(UroToday.com) HPN424 is a prostate-specific membrane antigen (PSMA)-targeting T cell engager designed to redirect T cells to kill PSMA-expressing prostate cancer cells. It is engineered with three binding domains: anti-PSMA for tumor cell engagement, anti-albumin for half-life extension, and anti-CD3 for T cell engagement. Furthermore, HPN424 is optimized for small size and increased stability compared to […]

(UroToday.com) CCW702 is a novel bispecific antibody comprised of a small molecule imaging agent ligand (DUPA) with specificity for prostate-specific membrane antigen (PSMA) conjugated to an anti-CD3 antibody via an unnatural amino acid. This format has the structure of an antibody drug conjugate with the activity of a CD3-engaging bispecific antibody.